These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38175597)

  • 1. Critical Factors in the Analytical Work Flow of Circulating Tumor DNA-Based Molecular Profiling.
    van der Leest P; Schuuring E
    Clin Chem; 2024 Jan; 70(1):220-233. PubMed ID: 38175597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
    Lampignano R; Neumann MHD; Weber S; Kloten V; Herdean A; Voss T; Groelz D; Babayan A; Tibbesma M; Schlumpberger M; Chemi F; Rothwell DG; Wikman H; Galizzi JP; Riise Bergheim I; Russnes H; Mussolin B; Bonin S; Voigt C; Musa H; Pinzani P; Lianidou E; Brady G; Speicher MR; Pantel K; Betsou F; Schuuring E; Kubista M; Ammerlaan W; Sprenger-Haussels M; Schlange T; Heitzer E
    Clin Chem; 2020 Jan; 66(1):149-160. PubMed ID: 31628139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling.
    van der Leest P; Ketelaar EM; van Noesel CJM; van den Broek D; van Boerdonk RAA; Deiman B; Rifaela N; van der Geize R; Huijsmans CJJ; Speel EJM; Geerlings MJ; van Schaik RHN; Jansen MPHM; Dane-Vogelaar R; Driehuis E; Leers MPG; Sidorenkov G; Tamminga M; van Kempen LC; Schuuring E
    Clin Chem; 2022 Jul; 68(7):963-972. PubMed ID: 35616097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cfDNA.
    Danesi R; Lo YMD; Oellerich M; Beck J; Galbiati S; Re MD; Lianidou E; Neumaier M; van Schaik RHN
    Clin Chim Acta; 2021 Sep; 520():168-171. PubMed ID: 34081934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations.
    Andersson D; Kristiansson H; Kubista M; Ståhlberg A
    Expert Rev Mol Diagn; 2021 Mar; 21(3):299-310. PubMed ID: 33683971
    [No Abstract]   [Full Text] [Related]  

  • 7. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis.
    Ntzifa A; Lianidou E
    Crit Rev Clin Lab Sci; 2023 Dec; 60(8):573-594. PubMed ID: 37518938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA in cancer: current insights.
    Fettke H; Kwan EM; Azad AA
    Cell Oncol (Dordr); 2019 Feb; 42(1):13-28. PubMed ID: 30367445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
    Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
    JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
    Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
    Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients.
    Leest PV; Janning M; Rifaela N; Azpurua MLA; Kropidlowski J; Loges S; Lozano N; Sartori A; Irwin D; Lamy PJ; Hiltermann TJN; Groen HJM; Pantel K; Kempen LCV; Wikman H; Schuuring E
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients.
    Huang RSP; Xiao J; Pavlick DC; Guo C; Yang L; Jin DX; Fendler B; Severson E; Killian JK; Hiemenz M; Duncan D; Lin DI; Dennis L; Aiyer A; Gjoerup O; Oxnard G; Venstrom J; Elvin J; Ramkissoon SH; Ross JS
    Clin Chem; 2021 Nov; 67(11):1554-1566. PubMed ID: 34626187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine.
    Kerachian MA; Poudineh A; Thiery JP
    Crit Rev Oncol Hematol; 2019 Dec; 144():102827. PubMed ID: 31715326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
    Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
    Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.
    Lee JS; Cho EH; Kim B; Hong J; Kim YG; Kim Y; Jang JH; Lee ST; Kong SY; Lee W; Shin S; Song EY;
    Ann Lab Med; 2024 May; 44(3):195-209. PubMed ID: 38221747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.